105
Participants
Start Date
January 11, 2016
Primary Completion Date
December 27, 2025
Study Completion Date
December 27, 2025
cemiplimab
Administration via intravenous (IV) infusion. The dose(s) received will be according to dose level (DL) cohort assignment, as described in the protocol.
odronextamab
Administration IV infusion. The dose(s) received will be according to DL cohort assignment, as described in the protocol.
Medical University Vienna, Vienna
Uniklinikum Salzburg (LKH) Universitatsklinik fur Innere Medizin III, Salzburg
Universitatsklinikum Jena, Jena
Johns Hopkins University, Baltimore
Universitatsklinikum Schleswig-Holstein, Campus Kiel, Kiel
MD Anderson Cancer Center- Madrid, Madrid
Hospital Universitario Fundacion Jimenez Diaz, Madrid
Hospital Universitario 12 de Octubre, Madrid
Hospital Universitario Puerta de Hierro - Majadahonda, Majadahonda
Hospital Universitario Quironsalud Madrid, Pozuelo de Alarcón
Hospital Clinico Universitario de Salamanca, Salamanca
University Hospitals Cleveland Medical Center, Cleveland
Cancer & Hematology Centers of Western Michigan, Grand Rapids
University Hospital Frankfurt, Frankfurt am Main
Tel Aviv Sourasky Medical Center, Tel Aviv
Soroka, Beersheba
Hadassah Medical Center, Jerusalem
Chaim Sheba Medical Center, Ramat Gan
Dana Farber/Harvard Cancer Center - PO box 849168, Boston
Harvard Medical School - Beth Israel Deaconess Medical Center, Boston
Pratia MCM Krakow, Krakow
Uniwersyteckie Centrum Kliniczne, Gdansk
Pratia Onkologia Katowice, Katowice
Copernicus Memorial Hospital, Lodz
Narodowy Instytut Onkologii im Marii Sklodowskiej Curie Panstwowy Instytut Badawczy Warszawa, Warsaw
Hospital Universitario Marques de Valdecilla, Santander
Hospital Universitario Vall d'Hebron, Barcelona
Hospital Clinic de Barcelona, Barcelona
Hospital de la Santa Creu i Sant Pau, Barcelona
Institut Catala dOncologia (ICO Hospitalet), Barcelona
Regeneron Pharmaceuticals
INDUSTRY